TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improved health benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergence of signs of irritability and sensitization in the genital mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Concordance rate for the wound and the type of dressing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium content of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Heart Failure (HF) Event
Endpoint domain: Mortality/survival
Primary endpoint: Global scores on Clinician Administered PTSD Scale - One Week Symptom Version (CAPS-SX)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: alteration of gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung inflammatory mediators levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severe Intimate Partner Violence
Endpoint domain: Adverse events/effects
Primary endpoint: Condom Use
Endpoint domain: Resource use
Primary endpoint: Presence of Methicillin-Resistant Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Abnormal neural circulatory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abnormal respiratory control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to wearing the activity monitor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: prolonged intraoperative cerebral desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PADYQ score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of metastatic disease
Endpoint domain: Mortality/survival
Primary endpoint: Degree of cellularity in biopsy sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of wound surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Difference in peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: analgesic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: WOMAC Pain Subscale Change From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in sway area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CoP displacement amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CoP velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Time Travel Ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time Estimation Ability - long intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time Estimation Ability - short intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time Reproduction Ability - long intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time Reproduction Ability - short intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the acceptability and liking of grain products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the gut microbiota and their fermentation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of volunteers with humoral and cellular immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of solicited and non solicited adverse events following immunization
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in AST Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent Change in ALT Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent Change in Alkaline Phosphatase Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent Change in Prothrombin Times (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent Change in Bilirubin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Decrease in Hepatobiliary Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Predicted Percentage of Remaining Pulmonary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Bleeding on Probe to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Plaque Index to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pocket Probing Depth to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with electrocardiographic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical attachment level in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probing pocket depth in mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence or absence of bleeding on probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of actionable alterations in cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Individualized treatment recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Oxygen Radical Absorbance Capacity Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Trolox Equivalent Antioxidant Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Serum Retinol Determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change Serum pro-VA carotenoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to increase haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Attitude towards blood donation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood clotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MOAKS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Percent serum hCG decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complain of Headache during last 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Sexual Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in 1-hour morning post-dose FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in morning pre-dose (trough) FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of PASI (psoriasis activity score index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Events of Acute Urinary Retention (AUR) or BPH-related Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Patient satisfaction with Urovac device
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient perception of urine spills after using Urovac
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Clinician perception of Urovac effectiveness in avoiding foley catheterization or condom catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and tolerability of WET® gel
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects as Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to SARS-CoV-2 eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to clinical improvement of subjective symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distance walked during six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Global Impression - Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Global Impression of Severity (PGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Sinonasal outcome test (SNOT) 20 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Thrombus area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for Invasive Mechanical Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: compliance of psychoactive medicine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effect of Imatinib mesylate treatment on life threatening rare diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-Specific Antigen (PSA) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distracted driving behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Effects of early rehabilitation and deambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete and partial response rate according to the International Workshop Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFib recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: polarization sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of B17MP, formoterol and glycopyrrolate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ML COP Velocity From Baseline to Post Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ML COP Velocity From Baseline to Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AP COP Velocity From Baseline to Post Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AP COP Velocity From Baseline to Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ML TTB From Baseline to Post Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ML TTB From Baseline to Follow-Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Status of Fitbit® use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systemic Inflammatory Response Syndrome (SIRS) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial growth at glove cuff site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) AUC (0-12 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Free of Type I Complications at 180 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Pass Induced VF Conversion Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean 24h neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subcutaneous infliximab levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Urine culture orders per 1,000 resident-days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antibiotic starts for treatment of suspected UTI per 1,000 resident-days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment recommendation impact
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Percentage of Participants With Drug-Related Adverse Events Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of nilotinib-based therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of self-assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response rate in terms of plasmacytoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in scoring on Children's Organizational Skills Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Organizational Skills Scale-Parent (COSS-P)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Children's Organizational Skills Scale- (COSS-C)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Organizational Skills Scale-Teacher (COSS-T)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Homework Problem Checklist (HPCL) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in score on Academic Progress Report (APR)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Level 3 Postoperative Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Goals Attainments Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: World health organization quality of life- Brief
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Zarit Burden Interview- Arabic Abridged version
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: reduction in pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time (Hours) From Induction to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of bronchial allergen challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Signal repeatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC-CV>20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise tolerance measured by VO2peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Achieved Complete Immune Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of using SPECT-LM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pentraxin 3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Interval (PFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oedema Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on a disease activity rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantity of blood lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive sequelae
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Medication dose per cured patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial Glucose Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: detection rate of OLGIM stage by pCLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: detection rate of OLGIM stage by WLE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in mean 24-hour ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in vital signs (blood pressure [BP], pulse rate [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 12-lead ECG (electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in just noticeable difference threshold of proprioceptive sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of position sense of the knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Unified Parkinson's disease rating scale-motor (UPDRS motor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of balance function (measured by Functional Reach Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mobility function (measured by Time up and go test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functioning fistula for haemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: global impact of COVID-19 on baseline patients number
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: frequency of SARS-CoV-2 infection in healthcare workers
Endpoint domain: Adverse events/effects
Primary endpoint: Change in trans-diaphragmatic pressure generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in plantar flexor muscle group torque generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: maximal viral load reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of microembolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of radiographic healing of the periapical lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Opioids administered for pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total monetary amount won
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reaction times (milliseconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palonosetron Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dry bed days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pruritus (itch) severity assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability and responsiveness of DAT symptoms scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrograde ejaculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Efficacy as measured by image resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes